Acquisition of oncology antibody company EuChloe Bio provides Tessa Therapeutics with additional and complementary capabilities to extend its core technologies to treat a broad range of cancers

EuChloe Bio (EuChloe) is a biotechnology company specializing in the discovery and engineering of humanized monoclonal antibodies. With this acquisition, Tessa Therapeutics now possesses a pipeline of novel antibodies that are able to enhance and widen the application of its cellular immunotherapies to treat a broader range of cancer indications.